A Phase 2 interventional study of CTP-543 and Placebo in Alopecia Areata, sponsored by Concert Pharmaceuticals. Completed at 39 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-10-09.
Sponsored by Concert Pharmaceuticals (part of Sun Pharmaceutical Industries Limited) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing deuruxolitinib in Alopecia Areata — 2 open to participants now, 3 under way, 3 of them phase 3. Deuruxolitinib · Alopecia Areata.
Among the 10 studies testing deuruxolitinib in Alopecia Areata, this one is the 6th largest by enrollment, is one of 3 that started in 2021, is one of 4 in phase 2, and was the 6th registered.
220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.
Browse Alopecia Areata studies →2 of the 10 studies testing deuruxolitinib in Alopecia Areata are open now, in 3 countries. Recruiting first, the newest first:
Sun Pharma Japan Limited · Sites in Japan
Ages 18–65
Sun Pharmaceutical Industries, Inc. · Sites in United States, Canada
Ages 12–17
By country, each count listing its studies:
Deuruxolitinib: first FDA approval 2024 (LEQSELVI). What it is approved for, and how studies give it, is on its page →
Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 6
First in 2017; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 317 is above the median of 50 across 171 interventional studies indexed under Alopecia Areata.
Median enrollment 336 across the 10 interventional studies. Of the 7 that completed or were terminated, 7 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 3 most frequent:
This study is registered under Concert Pharmaceuticals, one of the names counted as Sun Pharmaceutical Industries Limited. Under that name alone:
Concert Pharmaceuticals is the lead sponsor of 33 studies on the registry; none are open to participants now.
Of its 20 completed or terminated interventional studies of FDA-regulated products, 7 (35%) have results posted.
10 studies in Alopecia Areata by Sun Pharmaceutical Industries Limited: 2 open now, 3 under way, 3 of them phase 3. Of 7 finished, 7 (100%) have results posted.
Among the 10 studies in Alopecia Areata by Sun Pharmaceutical Industries Limited, this one is the 6th largest by enrollment, is one of 3 that started in 2021, is one of 4 in phase 2, and was the 6th registered.
Sun Pharmaceutical Industries Limited’s Alopecia Areata studies by the year they started, since 2017.
1 of the studies testing deuruxolitinib in Alopecia Areata that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03898479Phase 3Sun Pharmaceutical Industries, Inc.Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing deuruxolitinib in Alopecia Areata, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sun Pharmaceutical Industries Limited’s 10 in Alopecia Areata:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is designed to evaluate the regrowth of hair with CTP-543 and subsequent durability of that regrowth following dose reduction in adult patients with moderate to severe alopecia areata.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received CTP-543 8 milligrams (mg) tablets, orally, twice daily (BID) for up to 24 weeks.
Drug: CTP-543
Participants received CTP-543 12 mg tablets, orally, BID for up to 24 weeks.
Drug: CTP-543
Participants who received CTP-543 8 mg during Period 1 of Part A and achieved an absolute severity of alopecia tool (SALT) score of ≤20 at Week 24, received CTP-543 4 mg tablets, orally, BID, for up to 24 weeks.
Drug: CTP-543
Participants who received CTP-543 12 mg during Period 1 of Part A and achieved an absolute SALT score of ≤20 at Week 24, received CTP-543 8 mg tablets, orally, BID, for up to 24 weeks.
Drug: CTP-543
Participants who received CTP-543 8 mg during Period 1 of Part A and achieved an absolute SALT score of ≤20 at Week 24, received CTP-543 matched placebo tablets, orally, BID, for up to 24 weeks.
Drug: Placebo
Participants who received CTP-543 12 mg during Period 1 of Part A and achieved an absolute SALT score of ≤20 at Week 24, received CTP-543 matched placebo tablets, orally, BID, for up to 24 weeks.
Drug: Placebo
Participants who received CTP-543 8 mg during Period 1, followed by CTP-543 4 mg during Period 2 of Part A and met the criteria for loss of regrowth maintenance (LOM) (absolute SALT score of \> 20), received re-treatment with CTP-543 8 mg tablets, orally, BID, for up to 24 weeks.
Drug: CTP-543
Participants who received CTP-543 12 mg during Period 1, followed by CTP-543 8 mg during Period 2 of Part A and met the criteria for LOM (absolute SALT score of \> 20), received re-treatment with CTP-543 12 mg tablets, orally, BID, for up to 24 weeks.
Drug: CTP-543
Participants who received CTP-543 8 mg during Period 1, followed by CTP-543 matched placebo during Period 2 of Part A and met the criteria for LOM (absolute SALT score of \> 20), received re-treatment with CTP-543 8 mg tablets, orally, BID, for up to 24 weeks.
Drug: CTP-543
Participants who received CTP-543 12 mg during Period 1, followed by CTP-543 matched placebo during Period 2 of Part A and met the criteria for LOM (absolute SALT score of \> 20), received re-treatment with CTP-543 12 mg tablets, orally, BID, for up to 24 weeks.
Drug: CTP-543
Oral dosing
Oral dosing
Part A, Period 2: Percentage of Participants Achieving Loss of Regrowth Maintenance (LOM) Criteria Defined by Severity of Alopecia Tool (SALT) Score > 20 Following Dose Reduction
SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss). LOM is defined as an absolute SALT score \>20. The percentage of participants achieving LOM criteria (SALT \>20) was compared to the percentage of participants maintaining treatment success (SALT ≤ 20) for each of the following dose reduction conditions. Due to the variable time on study for each participant within Part A Period 2, the primary analysis visit was the end of Part A Period 2, where the last observed non-missing SALT value was selected for each participant.
Time frame: From Week 24 to Week 48
Part A, Period 2: Percentage of Participants Achieving LOM Criteria Defined by SALT Score > 20 Following Drug Discontinuation
SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss). LOM is defined as an absolute SALT score \>20. The percentage of participants achieving LOM criteria (SALT \>20) was compared to the percentage of participants maintaining treatment success (SALT ≤ 20) for each of the following dose discontinuation conditions. Due to the variable time on study for each participant within Part A Period 2, the primary analysis visit was at the end of Part A Period 2, where the last observed non-missing SALT value was selected for each participant.
Time frame: From Week 24 to Week 48
Part B: Percentage of Participants by Dose Group Who Achieved Restoration of Regrowth (ROR) at Week 24
SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss). ROR is defined as the participant's attainment of an absolute SALT score of ≤20 at Week 24 of re-treatment.
Time frame: Week 24 of re-treatment
Part A, Period 2: Percentage of Participants Who Achieved LOM Criteria Defined by SALT Score > 20 Following Dose Reduction Conditions at Weeks 28, 32, 36, 40, 44, and 48
SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss). LOM is defined as an absolute SALT score \>20.
Time frame: Weeks 28, 32, 36, 40, 44, and 48
Part A, Period 2: Percentage of Participants Who Achieved LOM Criteria Defined by SALT > 20 Following Drug Discontinuation Conditions at Weeks 28, 32, 36, 40, 44, and 48
SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss). LOM is defined as an absolute SALT score \>20.
Time frame: Weeks 28, 32, 36, 40, 44, and 48
Part A, Period 1: Percentage of Responders as Assessed on the Hair Satisfaction Patient Reported Outcome (SPRO) Scale at Weeks 12, 16, 20, and 24
SPRO is a questionnaire answered by the participant and designed to measure how satisfied alopecia areata participants are with their hair at the time of the assessment. The responses range from 1 to 5: 1= very satisfied, 2= satisfied, 3= neither satisfied nor dissatisfied, 4= dissatisfied, and 5= very dissatisfied. SPRO responder is defined as a post-baseline response of 'very satisfied' or 'satisfied'.
Time frame: Weeks 12, 16, 20, and 24
Part A, Period 1: Percentage of Participants Who Achieved an Absolute SALT Score ≤20 at Weeks 4, 8, 12, 16, 20, and 24
SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).
Time frame: Weeks 4, 8, 12, 16, 20, and 24
Part A, Period 1: Relative Change in SALT Scores From Baseline at Weeks 4, 8, 12, 16, 20, and 24
SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss). Relative change (percent change) to baseline is calculated as: 100 x (\[post-baseline SALT score - baseline SALT score\]/baseline SALT score). Negative change indicates no hair loss.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24
Part A, Period 1: Percentage of Responders Assessed Using the Clinician Global Impression of Improvement (CGI-I) at Weeks 12, 16, 20 and 24
The CGI-I is a questionnaire that asks the clinician to evaluate the improvement or worsening of the participant's alopecia areata as compared to the start of the study on a 7-point scale. Responses range from 1 (very much worse) to 7 (very much improved). Responders were defined as participants with responses of 6 (much improved) or 7 (very much improved).
Time frame: Weeks 12, 16, 20, and 24
Part A, Period 1: Percentage of Responders Assessed Using the Patient Global Impression of Improvement (PGI-I) at Weeks 12, 16, 20, and 24
The PGI-I is a self-administered questionnaire that asks the participant to evaluate the improvement or worsening of their alopecia areata as compared to the start of the study on a 7-point scale. Responses range from 1 (very much worse) to 7 (very much improved). Responders were defined as participants with responses of 6 (much improved) or 7 (very much improved). PGI responder is a response of 'very much improved' or 'much improved'.
Time frame: Weeks 12, 16, 20, and 24
Part A, Period 1: Change in the Clinician Global Impression of Severity (CGI-S) Scores From Baseline at Weeks 12, 16, 20, and 24
The CGI-S is a questionnaire that asks the clinician to evaluate the symptom severity of the participant's alopecia areata at the time of assessment. The symptom severity was rated on a scale ranging from 1 to 7, where 1=normal, no hair loss; 2=borderline hair loss; 3=mild hair loss; 4=moderate hair loss; 5=marked hair loss; 6=severe hair loss; 7=among the most extreme hair loss. Higher scores indicate more hair loss. A negative change from baseline indicates less hair loss.
Time frame: Baseline, Weeks 12, 16, 20, and 24
Part A, Period 1: Change in the Patient Global Impression of Severity (PGI-S) Scores From Baseline at Weeks 12, 16, 20, and 24
The PGI-S is a self-administered questionnaire that asks the participant to evaluate the symptom severity of their alopecia areata at the time of assessment. Symptom severity was rated on a scale ranging from 1 to 7, where 1=normal, no hair loss; 2=borderline hair loss; 3=mild hair loss; 4=moderate hair loss; 5=marked hair loss; 6=severe hair loss; 7=among the most extreme hair loss. Higher scores indicate more hair loss. A negative change from baseline indicates less hair loss.
Time frame: Baseline, Weeks 12, 16, 20, and 24
Part A, Period 1: Change in the Individual Items of the Hair Quality Patient Reported Outcome (QPRO) Scale From Baseline at Weeks 12, 16, 20, and 24
The QPRO questionnaire provides additional details on key attributes of hair and helps provide context to the SPRO response. The individual items of QPRO are: Satisfied thickness hair coverage; Satisfied evenness hair coverage; How satisfied with your eyebrows; How satisfied with your eyelashes, scored on a scale ranging from 1 to 5 where 1=very satisfied, 2=satisfied, 3=neither satisfied nor dissatisfied, 4=dissatisfied, 5=very dissatisfied. Higher scores indicates the greater dissatisfaction on hair quality. A negative change from baseline indicate the greater satisfaction on hair quality.
Time frame: Baseline, Weeks 12, 16, 20, and 24
Part B: Percentage of Participants Who Achieved Restoration of Regrowth Criteria at Weeks 4, 8, 12, 16, 20, and 24
SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss). ROR is defined as the participant's attainment of an absolute SALT score of ≤20 during re-treatment.
Time frame: Weeks 4, 8, 12, 16, 20, and 24 of re-treatment
Part B: Relative Change in SALT Scores From Part B Baseline at Weeks 4, 8, 12, 16, 20, and 24
SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss). Relative change (percent change) to baseline is calculated as: 100 x (\[post-baseline SALT score - baseline SALT score\]/baseline SALT score).
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24 of re-treatment
Number of Participants Experiencing at Least One Treatment-Emergent Adverse Events (TEAEs)
An adverse event is any untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the patient's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a pre-existing condition) should be considered an adverse event. TEAEs were defined as any adverse event that occurs after administration of the first dose of study drug in each Part/Period (ie, on or after the day of the first dose in each Part/Period). TEAEs included both serious and non-serious TEAEs.
Time frame: From first dose of study drug up to last follow up visit (Week 76)
Participants were enrolled at study centers in the United States from 26 February 2021 to 16 May 2023.
| Milestone | Part A: Period 1 - CTP-543 8 mg BID | Part A: Period 1 - CTP-543 12 mg BID | Part A: Period 2 - CTP-543 8 mg BID to 4 mg BID | Part A: Period 2 - CTP-543 12 mg BID to 8 mg BID | Part A: Period 2 - CTP-543 8 mg BID to Placebo | Part A: Period 2 - CTP-543 12 mg BID to Placebo | Part B: CTP-543 8 mg BID to 4 mg BID to 8 mg BID | Part B: CTP-543 12 mg BID to 8 mg BID to 12 mg BID | Part B: CTP-543 8 mg BID to Placebo to 8 mg BID | Part B: CTP-543 12 mg BID to Placebo to 12 mg BID |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 180 | 137 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Efficacy population | 178 | 135 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 162 | 118 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 18 | 19 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Treatment emergent or worsening adverse event | 6 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Non-compliance with study drug | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Reason not specified | 5 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 5 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A: Period 1 - CTP-543 8 mg BID | Part A: Period 1 - CTP-543 12 mg BID | Part A: Period 2 - CTP-543 8 mg BID to 4 mg BID | Part A: Period 2 - CTP-543 12 mg BID to 8 mg BID | Part A: Period 2 - CTP-543 8 mg BID to Placebo | Part A: Period 2 - CTP-543 12 mg BID to Placebo | Part B: CTP-543 8 mg BID to 4 mg BID to 8 mg BID | Part B: CTP-543 12 mg BID to 8 mg BID to 12 mg BID | Part B: CTP-543 8 mg BID to Placebo to 8 mg BID | Part B: CTP-543 12 mg BID to Placebo to 12 mg BID |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 18 | 25 | 18 | 25 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 17 | 25 | 18 | 25 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A: Period 1 - CTP-543 8 mg BID | Part A: Period 1 - CTP-543 12 mg BID | Part A: Period 2 - CTP-543 8 mg BID to 4 mg BID | Part A: Period 2 - CTP-543 12 mg BID to 8 mg BID | Part A: Period 2 - CTP-543 8 mg BID to Placebo | Part A: Period 2 - CTP-543 12 mg BID to Placebo | Part B: CTP-543 8 mg BID to 4 mg BID to 8 mg BID | Part B: CTP-543 12 mg BID to 8 mg BID to 12 mg BID | Part B: CTP-543 8 mg BID to Placebo to 8 mg BID | Part B: CTP-543 12 mg BID to Placebo to 12 mg BID |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 8 | 15 | 19 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 8 | 13 | 18 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Reason not specified | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss). LOM is defined as an absolute SALT score \>20. The percentage of participants achieving LOM criteria (SALT \>20) was compared to the percentage of participants maintaining treatment success (SALT ≤ 20) for each of the following dose reduction conditions. Due to the variable time on study for each participant within Part A Period 2, the primary analysis visit was the end of Part A Period 2, where the last observed non-missing SALT value was selected for each participant.
| Percentage of participants | Part A: Period 2 - CTP-543 8 mg BID to 4 mg BID | Part A: Period 2 - CTP-543 12 mg BID to 8 mg BID |
|---|---|---|
| Part A, Period 2: Percentage of Participants Achieving Loss of Regrowth Maintenance (LOM) Criteria Defined by Severity of Alopecia Tool (SALT) Score > 20 Following Dose Reduction | 27.8 (7.1 to 48.5) | 32.0 (13.7 to 50.3) |
SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss). LOM is defined as an absolute SALT score \>20. The percentage of participants achieving LOM criteria (SALT \>20) was compared to the percentage of participants maintaining treatment success (SALT ≤ 20) for each of the following dose discontinuation conditions. Due to the variable time on study for each participant within Part A Period 2, the primary analysis visit was at the end of Part A Period 2, where the last observed non-missing SALT value was selected for each participant.
| Percentage of participants | Part A: Period 2 - CTP-543 8 mg BID to Placebo | Part A: Period 2 - CTP-543 12 mg BID to Placebo |
|---|---|---|
| Part A, Period 2: Percentage of Participants Achieving LOM Criteria Defined by SALT Score > 20 Following Drug Discontinuation | 83.3 (66.1 to 100.0) | 80.0 (64.3 to 95.7) |
SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss). ROR is defined as the participant's attainment of an absolute SALT score of ≤20 at Week 24 of re-treatment.
| Percentage of participants | Part B: CTP-543 8 mg BID to 4 mg BID to 8 mg BID | Part B: CTP-543 12 mg BID to 8 mg BID to 12 mg BID | Part B: CTP-543 8 mg BID to Placebo to 8 mg BID | Part B: CTP-543 12 mg BID to Placebo to 12 mg BID |
|---|---|---|---|---|
| Part B: Percentage of Participants by Dose Group Who Achieved Restoration of Regrowth (ROR) at Week 24 | 60.0 (17.1 to 100.0) | 50.0 (15.4 to 84.6) | 66.7 (54.0 to 99.8) | 73.7 (58.6 to 97.0) |
SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss). LOM is defined as an absolute SALT score \>20.
| Percentage of participants | Part A: Period 2 - CTP-543 8 mg BID to 4 mg BID | Part A: Period 2 - CTP-543 12 mg BID to 8 mg BID |
|---|---|---|
| Week 28 | 0 (NA to NA) | 12 (2.5 to 31.2) |
| Week 32 | 6.3 (0.2 to 30.2) | 4.5 (0.1 to 22.8) |
| Week 36 | 0 (NA to NA) | 4.8 (0.1 to 23.8) |
| Week 40 | 12.5 (1.6 to 38.3) | 10.5 (1.3 to 33.1) |
| Week 44 | 7.7 (0.2 to 36.0) | 0 (NA to NA) |
| Week 48 | 7.7 (0.2 to 36.0) | 5.6 (0.1 to 27.3) |
SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss). LOM is defined as an absolute SALT score \>20.
| Percentage of participants | Part A: Period 2 - CTP-543 8 mg to Placebo | Part A, Period 2 - CTP-543 12 mg to CTP-543 Matched Placebo |
|---|---|---|
| Week 28 | 0 (NA to NA) | 16.7 (4.7 to 37.4) |
| Week 32 | 16.7 (3.6 to 41.4) | 14.3 (3.0 to 36.3) |
| Week 36 | 26.7 (7.8 to 55.1) | 43.8 (19.8 to 70.1) |
| Week 40 | 36.4 (10.9 to 69.2) | 22.2 (2.8 to 60.0) |
| Week 44 | 28.6 (3.7 to 71.0) | 0 (NA to NA) |
| Week 48 | 40.0 (5.3 to 85.3) | 28.6 (3.7 to 71.0) |
SPRO is a questionnaire answered by the participant and designed to measure how satisfied alopecia areata participants are with their hair at the time of the assessment. The responses range from 1 to 5: 1= very satisfied, 2= satisfied, 3= neither satisfied nor dissatisfied, 4= dissatisfied, and 5= very dissatisfied. SPRO responder is defined as a post-baseline response of 'very satisfied' or 'satisfied'.
| Percentage of participants | Part A: Period 1 - CTP-543 8 mg BID | Part A: Period 1 - CTP-543 12 mg BID |
|---|---|---|
| Week 12 | 24.0 (17.6 to 30.4) | 40.2 (31.6 to 48.7) |
| Week 16 | 26.9 (20.2 to 33.7) | 39.1 (30.6 to 47.5) |
| Week 20 | 25.6 (18.9 to 32.3) | 52.0 (43.2 to 60.9) |
| Week 24 | 28.8 (21.9 to 35.8) | 48.7 (39.8 to 57.7) |
SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).
| Percentage of participants | Part A: Period 1 - CTP-543 8 mg BID | Part A: Period 1 - CTP-543 12 mg BID |
|---|---|---|
| Week 4 | 0 (NA to NA) | 0 (NA to NA) |
| Week 8 | 1.7 (0.0 to 3.7) | 2.3 (0.0 to 5.0) |
| Week 12 | 5.8 (2.3 to 9.3) | 16.4 (10.0 to 22.8) |
| Week 16 | 10.2 (5.6 to 14.8) | 24.2 (16.8 to 31.6) |
| Week 20 | 15.9 (10.3 to 21.4) | 35.2 (26.8 to 43.7) |
| Week 24 | 22.1 (15.7 to 28.5) | 42.9 (34.0 to 51.7) |
SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss). Relative change (percent change) to baseline is calculated as: 100 x (\[post-baseline SALT score - baseline SALT score\]/baseline SALT score). Negative change indicates no hair loss.
| Percent change | Part A: Period 1 - CTP-543 8 mg BID | Part A: Period 1 - CTP-543 12 mg BID |
|---|---|---|
| Relative Change From Baseline at Week 4 | -0.5 ± 11.17 | -1.0 ± 8.73 |
| Relative Change From Baseline at Week 8 | -7.4 ± 18.41 | -14.8 ± 21.67 |
| Relative Change From Baseline at Week 12 | -18.1 ± 27.42 | -30.9 ± 33.69 |
| Relative Change From Baseline at Week 16 | -26.3 ± 31.68 | -39.9 ± 36.24 |
| Relative Change From Baseline at Week 20 | -32.1 ± 34.26 | -49.0 ± 37.44 |
| Relative Change From Baseline at Week 24 | -38.2 ± 36.85 | -55.3 ± 38.01 |
The CGI-I is a questionnaire that asks the clinician to evaluate the improvement or worsening of the participant's alopecia areata as compared to the start of the study on a 7-point scale. Responses range from 1 (very much worse) to 7 (very much improved). Responders were defined as participants with responses of 6 (much improved) or 7 (very much improved).
| Percentage of responders | Part A: Period 1 - CTP-543 8 mg BID | Part A: Period 1 - CTP-543 12 mg BID |
|---|---|---|
| Week 12 | 26.7 (20.1 to 33.4) | 47.6 (38.9 to 56.3) |
| Week 16 | 37.7 (30.4 to 45.1) | 51.6 (42.9 to 60.2) |
| Week 20 | 47.6 (39.2 to 55.2) | 63.1 (54.6 to 71.7) |
| Week 24 | 50.3 (42.6 to 58.0) | 64.7 (56.1 to 73.3) |
The PGI-I is a self-administered questionnaire that asks the participant to evaluate the improvement or worsening of their alopecia areata as compared to the start of the study on a 7-point scale. Responses range from 1 (very much worse) to 7 (very much improved). Responders were defined as participants with responses of 6 (much improved) or 7 (very much improved). PGI responder is a response of 'very much improved' or 'much improved'.
| Percentage of responders | Part A: Period 1 - CTP-543 8 mg BID | Part A: Period 1 - CTP-543 12 mg BID |
|---|---|---|
| Week 12 | 29.8 (23.0 to 36.7) | 52.8 (44.1 to 61.4) |
| Week 16 | 33.5 (26.4 to 40.7) | 55.5 (46.9 to 64.1) |
| Week 20 | 40.9 (33.3 to 48.4) | 63.4 (54.9 to 71.9) |
| Week 24 | 46.0 (38.4 to 53.7) | 65.5 (57.0 to 74.1) |
The CGI-S is a questionnaire that asks the clinician to evaluate the symptom severity of the participant's alopecia areata at the time of assessment. The symptom severity was rated on a scale ranging from 1 to 7, where 1=normal, no hair loss; 2=borderline hair loss; 3=mild hair loss; 4=moderate hair loss; 5=marked hair loss; 6=severe hair loss; 7=among the most extreme hair loss. Higher scores indicate more hair loss. A negative change from baseline indicates less hair loss.
| Score on a scale | Part A: Period 1 - CTP-543 8 mg BID | Part A: Period 1 - CTP-543 12 mg BID |
|---|---|---|
| Baseline | 6.4 ± 0.78 | 6.3 ± 0.95 |
| Change From Baseline at Week 12 | -0.8 ± 1.15 | -1.4 ± 1.63 |
| Change From Baseline at Week 16 | -1.1 ± 1.37 | -1.8 ± 1.74 |
| Change From Baseline at Week 20 | -1.3 ± 1.38 | -2.1 ± 1.84 |
| Change From Baseline at Week 24 | -1.6 ± 1.64 | -2.4 ± 1.92 |
The PGI-S is a self-administered questionnaire that asks the participant to evaluate the symptom severity of their alopecia areata at the time of assessment. Symptom severity was rated on a scale ranging from 1 to 7, where 1=normal, no hair loss; 2=borderline hair loss; 3=mild hair loss; 4=moderate hair loss; 5=marked hair loss; 6=severe hair loss; 7=among the most extreme hair loss. Higher scores indicate more hair loss. A negative change from baseline indicates less hair loss.
| Score on a scale | Part A: Period 1 - CTP-543 8 mg BID | Part A: Period 1 - CTP-543 12 mg BID |
|---|---|---|
| Baseline | 6.4 ± 0.75 | 6.4 ± 0.84 |
| Change From Baseline at Week 12 | -0.8 ± 1.31 | -1.1 ± 1.56 |
| Change From Baseline at Week 16 | -1.0 ± 1.41 | -1.6 ± 1.74 |
| Change From Baseline at Week 20 | -1.1 ± 1.41 | -2.1 ± 1.78 |
| Change From Baseline at Week 24 | -1.4 ± 1.66 | -2.3 ± 1.95 |
The QPRO questionnaire provides additional details on key attributes of hair and helps provide context to the SPRO response. The individual items of QPRO are: Satisfied thickness hair coverage; Satisfied evenness hair coverage; How satisfied with your eyebrows; How satisfied with your eyelashes, scored on a scale ranging from 1 to 5 where 1=very satisfied, 2=satisfied, 3=neither satisfied nor dissatisfied, 4=dissatisfied, 5=very dissatisfied. Higher scores indicates the greater dissatisfaction on hair quality. A negative change from baseline indicate the greater satisfaction on hair quality.
| Score on a scale | Part A: Period 1 - CTP-543 8 mg BID | Part A: Period 1 - CTP-543 12 mg BID |
|---|---|---|
| Satisfied Thickness Hair Coverage: Baseline | 4.6 ± 0.74 | 4.6 ± 0.67 |
| Satisfied Thickness Hair Coverage: Change From Baseline at Week 12 | -0.9 ± 1.17 | -1.3 ± 1.15 |
| Satisfied Thickness Hair Coverage: Change From Baseline at Week 16 | -1.0 ± 1.15 | -1.5 ± 1.14 |
| Satisfied Thickness Hair Coverage: Change From Baseline at Week 20 | -1.1 ± 1.23 | -1.7 ± 1.16 |
| Satisfied Thickness Hair Coverage: Change From Baseline at Week 24 | -1.2 ± 1.38 | -1.7 ± 1.25 |
| Satisfied Evenness Hair Coverage: Baseline | 4.7 ± 0.62 | 4.7 ± 0.64 |
| Satisfied Evenness Hair Coverage: Change From Baseline at Week 12 | -0.8 ± 1.09 | -1.3 ± 1.09 |
| Satisfied Evenness Hair Coverage: Change From Baseline at Week 16 | -0.9 ± 1.07 | -1.4 ± 1.14 |
| Satisfied Evenness Hair Coverage: Change From Baseline at Week 20 | -1.0 ± 1.11 | -1.6 ± 1.19 |
| Satisfied Evenness Hair Coverage: Change From Baseline at Week 24 | -1.1 ± 1.22 | -1.7 ± 1.18 |
| How Satisfied With Your Eyebrows: Baseline | 4.0 ± 1.23 | 4.1 ± 1.35 |
| How Satisfied With Your Eyebrows: Change From Baseline at Week 12 | -0.8 ± 1.20 | -1.4 ± 1.43 |
| How Satisfied With Your Eyebrows: Change From Baseline at Week 16 | -1.0 ± 1.17 | -1.4 ± 1.44 |
| How Satisfied With Your Eyebrows: Change From Baseline at Week 20 | -1.0 ± 1.28 | -1.5 ± 1.32 |
| How Satisfied With Your Eyebrows: Change From Baseline at Week 24 | -1.1 ± 1.29 | -1.7 ± 1.42 |
| How Satisfied With Your Eyelashes: Baseline | 3.7 ± 1.40 | 3.7 ± 1.44 |
| How Satisfied With Your Eyelashes: Change From Baseline at Week 12 | -0.7 ± 1.12 | -1.1 ± 1.42 |
| How Satisfied With Your Eyelashes: Change From Baseline at Week 16 | -0.8 ± 1.25 | -1.3 ± 1.42 |
| How Satisfied With Your Eyelashes: Change From Baseline at Week 20 | -0.8 ± 1.22 | -1.4 ± 1.37 |
| How Satisfied With Your Eyelashes: Change From Baseline at Week 24 | -0.9 ± 1.28 | -1.5 ± 1.41 |
SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss). ROR is defined as the participant's attainment of an absolute SALT score of ≤20 during re-treatment.
| Percentage of participants | Part B: CTP-543 8 mg to 4 mg BID to 8 mg BID | Part B: CTP-543 12 mg BID to 8 mg BID to 12 mg BID | Part B: CTP-543 8 mg BID to Placebo to 8 mg BID | Part B: CTP-543 12 mg BID to Placebo to 12 mg BID |
|---|---|---|---|---|
| Week 4 | 60.0 (17.1 to 100.0) | 62.5 (29.0 to 96.0) | 26.7 (4.3 to 49.0) | 15.8 (0.0 to 32.2) |
| Week 8 | 100.0 (100.0 to 100.0) | 62.5 (29.0 to 96.0) | 23.1 (0.2 to 46.0) | 16.7 (0.0 to 33.9) |
| Week 12 | 80.0 (44.9 to 100.0) | 62.5 (29.0 to 96.0) | 30.8 (5.7 to 55.9) | 43.8 (19.4 to 68.1) |
| Week 16 | 60.0 (17.1 to 100.0) | 62.5 (29.0 to 96.0) | 50.0 (21.7 to 78.3) | 61.1 (38.6 to 83.6) |
| Week 20 | 60.0 (17.1 to 100.0) | 62.5 (29.0 to 96.0) | 69.2 (44.1 to 94.3) | 70.6 (48.9 to 92.2) |
| Week 24 | 60.0 (17.1 to 100.0) | 50.0 (15.4 to 84.6) | 76.9 (54.0 to 99.8) | 77.8 (58.6 to 97.0) |
SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss). Relative change (percent change) to baseline is calculated as: 100 x (\[post-baseline SALT score - baseline SALT score\]/baseline SALT score).
| Percent change | Part B: CTP-543 8 mg BID to 4 mg BID to 8 mg BID | Part B: CTP-543 12 mg BID to 8 mg BID to 12 mg BID | Part B: CTP-543 8 mg BID to Placebo to 8 mg BID | Part B: CTP-543 12 mg BID to Placebo to 12 mg BID |
|---|---|---|---|---|
| Relative Change From Baseline at Week 4 | -20.8 ± 15.27 | -1.5 ± 69.43 | 12.1 ± 39.44 | 47.8 ± 71.19 |
| Relative Change From Baseline at Week 8 | -39.6 ± 20.33 | 26.2 ± 109.97 | 10.5 ± 48.10 | 47.1 ± 94.35 |
| Relative Change From Baseline at Week 12 | -42.6 ± 27.06 | -2.6 ± 78.81 | -7.2 ± 84.41 | 33.9 ± 119.41 |
| Relative Change From Baseline at Week 16 | -48.8 ± 52.66 | -11.4 ± 78.88 | -13.4 ± 95.31 | -15.2 ± 116.20 |
| Relative Change From Baseline at Week 20 | -54.8 ± 43.90 | -7.8 ± 83.35 | -29.2 ± 93.24 | -31.5 ± 108.97 |
| Relative Change From Baseline at Week 24 | -39.3 ± 53.48 | -7.9 ± 81.41 | -39.3 ± 84.49 | -38.4 ± 105.80 |
An adverse event is any untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the patient's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a pre-existing condition) should be considered an adverse event. TEAEs were defined as any adverse event that occurs after administration of the first dose of study drug in each Part/Period (ie, on or after the day of the first dose in each Part/Period). TEAEs included both serious and non-serious TEAEs.
| Participants | Part A: Period 1 - CTP-543 8 mg BID | Part A: Period 1 - CTP-543 12 mg BID | Part A: Period 2 - CTP-543 8 mg BID to 4 mg BID | Part A: Period 2 - CTP-543 12 mg BID to 8 mg BID | Part A: Period 2 - CTP-543 8 mg BID to Placebo | Part A: Period 2 - CTP-543 12 mg BID to Placebo | Part B: CTP-543 8 mg BID to 4 mg BID to 8 mg BID | Part B: CTP-543 12 mg BID to 8 mg BID to 12 mg BID | Part B: CTP-543 8 mg BID to Placebo to 8 mg BID | Part B: CTP-543 12 mg BID to Placebo to 12 mg BID |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Experiencing at Least One Treatment-Emergent Adverse Events (TEAEs) | 124 | 100 | 9 | 12 | 7 | 11 | 2 | 5 | 12 | 14 |
Collected over From first dose of study drug up to last follow up visit (Week 76). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Period 1 - CTP-543 8 mg BID | 0/180 (0%) | 1/180 (0.6%) | 91/180 (50.6%) |
| Part A: Period 1 - CTP-543 12 mg BID | 0/137 (0%) | 5/137 (3.6%) | 82/137 (59.9%) |
| Part A: Period 2 - CTP-543 8 mg BID to 4 mg BID | 0/18 (0%) | 0/18 (0%) | 9/18 (50%) |
| Part A: Period 2 - CTP-543 12 mg BID to 8 mg BID | 0/25 (0%) | 0/25 (0%) | 10/25 (40%) |
| Part A: Period 2 - CTP-543 8 mg BID to Placebo | 0/18 (0%) | 2/18 (11.1%) | 7/18 (38.9%) |
| Part A: Period 2 - CTP-543 12 mg BID to Placebo | 0/25 (0%) | 0/25 (0%) | 9/25 (36%) |
| Part B: CTP-543 8 mg BID to 4 mg BID to 8 mg BID | 0/5 (0%) | 0/5 (0%) | 2/5 (40%) |
| Part B: CTP-543 12 mg BID to 8 mg BID to 12 mg BID | 0/8 (0%) | 0/8 (0%) | 5/8 (62.5%) |
| Part B: CTP-543 8 mg BID to Placebo to 8 mg BID | 0/15 (0%) | 0/15 (0%) | 12/15 (80%) |
| Part B: CTP-543 12 mg BID to Placebo to 12 mg BID | 0/19 (0%) | 0/19 (0%) | 14/19 (73.7%) |
| Event | Part A: Period 1 - CTP-543 8 mg BID | Part A: Period 1 - CTP-543 12 mg BID | Part A: Period 2 - CTP-543 8 mg BID to 4 mg BID | Part A: Period 2 - CTP-543 12 mg BID to 8 mg BID | Part A: Period 2 - CTP-543 8 mg BID to Placebo | Part A: Period 2 - CTP-543 12 mg BID to Placebo | Part B: CTP-543 8 mg BID to 4 mg BID to 8 mg BID | Part B: CTP-543 12 mg BID to 8 mg BID to 12 mg BID | Part B: CTP-543 8 mg BID to Placebo to 8 mg BID | Part B: CTP-543 12 mg BID to Placebo to 12 mg BID |
|---|---|---|---|---|---|---|---|---|---|---|
| Crohn's DiseaseGastrointestinal disorders | 0/180 | 0/137 | 0/18 | 0/25 | 1/18 | 0/25 | 0/5 | 0/8 | 0/15 | 0/19 |
| Suicidal IdeationPsychiatric disorders | 0/180 | 0/137 | 0/18 | 0/25 | 1/18 | 0/25 | 0/5 | 0/8 | 0/15 | 0/19 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/180 | 1/137 | 0/18 | 0/25 | 0/18 | 0/25 | 0/5 | 0/8 | 0/15 | 0/19 |
| ThrombocytosisBlood and lymphatic system disorders | 0/180 | 1/137 | 0/18 | 0/25 | 0/18 | 0/25 | 0/5 | 0/8 | 0/15 | 0/19 |
| Malignant Melanoma in SituNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/180 | 1/137 | 0/18 | 0/25 | 0/18 | 0/25 | 0/5 | 0/8 | 0/15 | 0/19 |
| Ankle FractureInjury, poisoning and procedural complications | 0/180 | 1/137 | 0/18 | 0/25 | 0/18 | 0/25 | 0/5 | 0/8 | 0/15 | 0/19 |
| Electrocardiogram T Wave InversionInvestigations | 0/180 | 1/137 | 0/18 | 0/25 | 0/18 | 0/25 | 0/5 | 0/8 | 0/15 | 0/19 |
| Pancreatic Carcinoma MetastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/180 | 0/137 | 0/18 | 0/25 | 0/18 | 0/25 | 0/5 | 0/8 | 0/15 | 0/19 |
| Event | Part A: Period 1 - CTP-543 8 mg BID | Part A: Period 1 - CTP-543 12 mg BID | Part A: Period 2 - CTP-543 8 mg BID to 4 mg BID | Part A: Period 2 - CTP-543 12 mg BID to 8 mg BID | Part A: Period 2 - CTP-543 8 mg BID to Placebo | Part A: Period 2 - CTP-543 12 mg BID to Placebo | Part B: CTP-543 8 mg BID to 4 mg BID to 8 mg BID | Part B: CTP-543 12 mg BID to 8 mg BID to 12 mg BID | Part B: CTP-543 8 mg BID to Placebo to 8 mg BID | Part B: CTP-543 12 mg BID to Placebo to 12 mg BID |
|---|---|---|---|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 23/180 | 21/137 | 3/18 | 5/25 | 0/18 | 0/25 | 0/5 | 1/8 | 4/15 | 4/19 |
| Candida infectionInfections and infestations | 0/180 | 0/137 | 0/18 | 0/25 | 0/18 | 0/25 | 1/5 | 1/8 | 0/15 | 0/19 |
| CostochondritisMusculoskeletal and connective tissue disorders | 0/180 | 0/137 | 0/18 | 0/25 | 0/18 | 0/25 | 1/5 | 0/8 | 0/15 | 0/19 |
| AcneSkin and subcutaneous tissue disorders | 23/180 | 17/137 | 0/18 | 1/25 | 0/18 | 0/25 | 1/5 | 0/8 | 0/15 | 0/19 |
| HeadacheNervous system disorders | 19/180 | 20/137 | 0/18 | 0/25 | 0/18 | 0/25 | 0/5 | 1/8 | 2/15 | 1/19 |
| Upper respiratory tract infectionInfections and infestations | 11/180 | 3/137 | 0/18 | 3/25 | 1/18 | 1/25 | 0/5 | 0/8 | 2/15 | 1/19 |
| Fungal skin infectionInfections and infestations | 0/180 | 0/137 | 0/18 | 0/25 | 0/18 | 0/25 | 0/5 | 1/8 | 0/15 | 0/19 |
| NasopharyngitisInfections and infestations | 11/180 | 10/137 | 0/18 | 3/25 | 0/18 | 3/25 | 0/5 | 1/8 | 1/15 | 1/19 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/180 | 2/137 | 1/18 | 0/25 | 1/18 | 0/25 | 0/5 | 1/8 | 1/15 | 0/19 |
| EczemaSkin and subcutaneous tissue disorders | 1/180 | 2/137 | 0/18 | 0/25 | 0/18 | 0/25 | 0/5 | 1/8 | 0/15 | 0/19 |
All randomized participants included all participants who were randomized in the study.
| Age, Continuous(years) | Part A: Period 1 - CTP-543 8 mg BID | Part A: Period 1 - CTP-543 12 mg BID | Total |
|---|---|---|---|
| Mean | 40.0 ± 14.05 | 39.6 ± 13.21 | 39.8 ± 13.68 |
| Sex: Female, Male(Participants) | Part A: Period 1 - CTP-543 8 mg BID | Part A: Period 1 - CTP-543 12 mg BID | Total |
|---|---|---|---|
| Female | 119 | 93 | 212 |
| Male | 61 | 44 | 105 |
| Ethnicity (NIH/OMB)(Participants) | Part A: Period 1 - CTP-543 8 mg BID | Part A: Period 1 - CTP-543 12 mg BID | Total |
|---|---|---|---|
| Hispanic or Latino | 13 | 11 | 24 |
| Not Hispanic or Latino | 167 | 126 | 293 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Part A: Period 1 - CTP-543 8 mg BID | Part A: Period 1 - CTP-543 12 mg BID | Total |
|---|---|---|---|
| Race — Asian | 14 | 9 | 23 |
| Race — Black or African American | 41 | 24 | 65 |
| Race — Native Hawaiian or other Pacific Islander | 1 | 0 | 1 |
| Race — White | 121 | 102 | 223 |
| Race — Other | 3 | 2 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2021 to primary completion in May 2023, 26 months.
Results were first posted in Oct 2024, 1 year 4 months after primary completion. A results delay was requested in Apr 2024.
Of 30 phase 2 interventional studies under Alopecia Areata, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 35. This study's 26 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Deuruxolitinib